Hopkins:
Speed of ComprehensionJune 11, 1998
WORLD'S FIRST PROCEDURE TO REPAIR BRAIN DAMAGE FROM STROKE PERFORMED AT THE UNIVERSITY OF PITTSBURGH MEDICAL CENTER Se også neste spalte på denne siden...
LBS-Neurons for Treating Stroke
|
Research Shows That OP-1 May Play an Important Role In The Treatment of StrokeHOPKINTON, Mass., July 16 /PRNewswire/ --
Creative BioMolecules, Inc.
First attempt to repair stroke damageUPI Science News PITTSBURGH, July 1 (UPI) - Researchers have implanted manufactured neurons into the brain of a stroke patient in the first attempt to repair the damage that causes paralysis. In the ground-breaking operation, doctors at the University of Pittsburgh said Wednesday they hoped the specially processed cells will eventually graft to the brain and form a connection to the patient's healthy areas and reverse the effects of the stroke. Researchers performed the procedure on a 62-year-old healthcare worker who suffered a major stroke last fall, leaving her with a paralyzed right arm and leg and the inability to speak. Patient Alma Cerasini is at home and so far is doing fine. Researchers said have no indication yet about the effectiveness of the procedure, performed June 23. She is the first of 12 patients in this earliest phase of the human trial, which tests for safety. Later trials would test the effectiveness, although scientists often get clues about the potential value of a procedure during the safetey phase. The human trial follows research published in February, in which a rat, who had received an implant of these same processed human cells, seemed to recover from its stroke in about a month. Last week, 2 million of these thawed out cells were implanted into the Cerasini's brain. "We've opened a door that's never been opened," Dr, Douglas Kondziolka, the performing surgeon, "because there's been no treatment for stroke on one hand and there's never been use of manufactured nerve cells on the other." Scientists have theorized since the mid-1980s that if healthy neurons could be implanted into damaged brain tissue that it might be possible to recover from stroke. One great hurdle to doing this was to get a large enough supply of specialized cells so they could do their job. Gary Snable, CEO of Layton BioSCience of Aptherton, Ca., said researchers solved that by using fast dividing tumor cells taken from a man who died of testicular and lung cancer 25 years ago. They then transformed a sufficient volume of them into non-dividing neurons that "had never seen a brain," said Snable. Research was carried on for eight years to determine if these neurons converted from cancer cells carried any danger of transferring cancer to animal transplant recipients. That did not happen. Except that the procedure put something in the brain instead of cutting something out, Kondziolka said, the procedure was relatively routine. The surgery involved drilling a hole in the head about the size of a tip of a ballpoint pen and implanting the neurons in the area of the brain that controls motor function. Cerasini was conscious throughout the procedure with a local anesthetic. If the operation works, Snable said he hopes it could become a common procedure in three to five years, Snable said. Because these cells are manufactured in a lab and not taken in a comparative rush, from either recently deceased donors or aborted embryos they can be more easily screened for impurities, Snable said. The plan, Snable told UPI, is to use manufactured cells that trace back to that one cancer victim who died in the 1970s.
|
Dr.
Finklestein commented regarding these findings, "While still in
the early stages of development, an OP-1 therapy may in the future provide physicians with a way of enhancing a patient's recovery from stroke. If similarly successful in human clinical trials, this would be a new tool in the treatment of stroke and represents an exciting new clinical avenue of research." Scientists at Creative BioMolecules and Harvard Medical School are working closely with research teams at academic institutions around the country to evaluate the potential applications of this new therapy. The preclinical data reported represents preliminary findings and will be confirmed in collaboration with other research teams. Creative BioMolecules is actively researching this product for the treatment of stroke as well as other neurological diseases. The statements in this news release are not historical facts and include forward-looking statements that involve risks and uncertainties. Factors which could cause actual results to differ from the Company's expectations include, without limitation, the course of the research and development programs, including the achievement of development milestones by the Company and completion of clinical testing, the impact of competitive products, the timely receipt of regulatory clearances required for clinical testing, manufacturing and marketing of products and the other risks and uncertainties detailed from time to time in the Company's periodic reports. Creative BioMolecules, Inc. is a discovery and development company focused on proprietary therapeutics for human tissue regeneration and restoration. The Company's therapeutics are based on proteins that act as signals in initiating and regulating the cellular events involved in tissue and organ formation. NOTE: Creative BioMolecules, Inc. makes available its latest news releases on the Internet at http://www.prnewswire.com or by facsimile by calling Fax On Demand at 1-800-758-5804, extension 212213. |
|
|